Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Omnicom Group Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Omnicom Group Inc. trades at $82 (market cap $23.35B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OMC | |
|---|---|---|
Market Cap | $39.89B | $23.35B |
Sector | Health | Media |
52-Week High | $491.22 | $85.80 |
52-Week Low | $278.09 | $67.27 |
Enterprise Value | $38.15B | $30.58B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Omnicom Group (OMC) trades at $81.93, up 1.36% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $105.75. The company reported revenue of $17.27 billion in 2025, though net income was negative $54.5 million, reflecting margin pressure. Recent news highlights major client wins, including IBM and Netflix partnerships, and strong free cash flow generation of $2.94 billion from operations.
OMC presents a value opportunity with a low P/E of 12.16 and positive earnings beats in recent quarters, but faces risks from intense competition and fluctuating profitability. The stock's upside potential is supported by analyst optimism and strategic expansions in AI and streaming advertising, though investors should monitor margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
